QLGN - Rasio utang marang kapitalisasi buku Qualigen Therapeutics Inc

Qualigen Therapeutics (QLGN) possesses high scientific authority in the development of antivirals and oncology drugs. Structural flexibility is ensured through the complete outsourcing of production and trials. The debt-to-market capitalization ratio confirms this model, with the value maintained at 0.08. The company is currently building an ecosystem for treating rare pathologies, the development of which depends directly on FDA regulatory decisions.

The ratio is calculated as total debt obligations relative to the book value of equity. This metric determines the extent to which asset financing depends on external creditors, characterizing overall financial stability. For a research-and-development startup like Qualigen Therapeutics (QLGN) with a boutique R&D culture, this is a critical marker of solvency. By analyzing the chart of debt obligations as a share of book capital, an investor assesses the risk of default. Consistently low values confirm the safety of the investment.